Azumino, Japan

Fumiya Tanada


 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Fumiya Tanada: Innovator in Pharmaceutical Chemistry

Fumiya Tanada is a notable inventor based in Azumino, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on pyrazole derivatives. His research focuses on developing compounds that can have therapeutic effects on various medical conditions.

Latest Patents

Fumiya Tanada holds a patent for a novel pyrazole derivative or a pharmaceutically acceptable salt thereof. This invention provides a pharmaceutical composition that includes the compound, which has been shown to possess TRPM8 inhibitory effects. The compound is represented by a specific formula and is useful in treating or preventing diseases caused by hyperexcitability or disorders of afferent neurons. This advancement has the potential to impact the treatment of various neurological conditions.

Career Highlights

Tanada is currently associated with Kissei Pharmaceutical Co., Ltd., where he continues to engage in groundbreaking research. His work has been instrumental in advancing the understanding of pyrazole derivatives and their applications in medicine. His dedication to innovation in pharmaceutical chemistry has established him as a key figure in his field.

Collaborations

Fumiya Tanada has collaborated with notable colleagues, including Hideaki Hirasawa and Yousuke Mutai. These collaborations have fostered a productive research environment, leading to significant advancements in their shared field of study.

Conclusion

Fumiya Tanada's contributions to pharmaceutical chemistry, particularly through his patent on pyrazole derivatives, highlight his role as an innovator in the industry. His work not only advances scientific knowledge but also holds promise for future medical applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…